| 23/09/25 | 16:59:26 | 23 Sept 2025 | | Proposed Placing to raise a minimum of £3 million |
| 23/09/25 | 09:00:00 | 23 Sept 2025 | | Holding(s) in Company |
| 23/09/25 | 09:00:00 | 23 Sept 2025 | | Holding(s) in Company |
| 15/09/25 | 16:24:40 | 15 Sept 2025 | | Result of General Meeting |
| 10/09/25 | 16:15:56 | 10 Sept 2025 | | Holding(s) in Company |
| 10/09/25 | 16:15:55 | 10 Sept 2025 | | Holding(s) in Company |
| 29/08/25 | 12:00:01 | 29 Aug 2025 | | Proposed Share Capital Reorganisation & GM |
| 21/08/25 | 07:00:08 | 21 Aug 2025 | | Scotland’s Public Health Minister visit |
| 14/08/25 | 10:35:59 | 14 Aug 2025 | | Comment re: Share Price Movement |
| 11/08/25 | 07:00:09 | 11 Aug 2025 | | Trading update |
| 30/05/25 | 07:00:11 | 30 May 2025 | | Block Listing Returns |
| 30/05/25 | 07:00:03 | 30 May 2025 | | CE-certification |
| 13/05/25 | 07:00:02 | 13 May 2025 | | CYP2C19-ID Kit used to support expansion |
| 02/05/25 | 13:30:00 | 2 May 2025 | | CYP2C19 ID Kit CE-IVD certification update |
| 02/04/25 | 07:01:01 | 2 Apr 2025 | | Additional grant funding under DEVOTE programme |
| 02/04/25 | 07:00:03 | 2 Apr 2025 | | Receipt of R&D tax credit |
| 01/04/25 | 07:00:07 | 1 Apr 2025 | | Result of RetailBook Offer |
| 27/03/25 | 15:30:26 | 27 Mar 2025 | | RetailBook Offer |
| 27/03/25 | 15:29:46 | 27 Mar 2025 | | Half-year Report |
| 27/03/25 | 15:28:00 | 27 Mar 2025 | | Equity Fundraise |
| 17/03/25 | 11:04:02 | 17 Mar 2025 | | Scottish Government testing programme investment |
| 14/03/25 | 07:00:02 | 14 Mar 2025 | | CYP2C19-ID Kit adopted for routine clinical use |
| 30/12/24 | 11:54:02 | 30 Dec 2024 | | Result of AGM |
| 27/12/24 | 07:00:06 | 27 Dec 2024 | | Genedrive® CYP2C19-ID Kit performance published |
| 20/12/24 | 12:16:40 | 20 Dec 2024 | | Grant of Options |
| 20/12/24 | 12:12:39 | 20 Dec 2024 | | Director/PDMR Shareholding |
| 05/12/24 | 15:00:00 | 5 Dec 2024 | | Posting of annual report and notice of AGM |
| 29/11/24 | 13:00:00 | 29 Nov 2024 | | Block listing returns |
| 29/11/24 | 07:00:05 | 29 Nov 2024 | | Final Results |
| 22/11/24 | 07:00:09 | 22 Nov 2024 | | Notice of Results |
| 21/11/24 | 11:06:45 | 21 Nov 2024 | | NIHR and OLS Funding Package |
| 05/11/24 | 10:53:57 | 5 Nov 2024 | | Department for Business and Trade feature |
| 04/11/24 | 13:29:55 | 4 Nov 2024 | | Scottish Health Technology Group publications |
| 21/10/24 | 15:22:55 | 21 Oct 2024 | | Director Declaration |
| 15/08/24 | 10:39:10 | 15 Aug 2024 | | Director/PDMR Shareholding |
| 12/08/24 | 07:00:04 | 12 Aug 2024 | | First UK commercial sales of the CYP2C19-ID Kit |
| 06/08/24 | 07:00:12 | 6 Aug 2024 | | Directorate Change |
| 31/07/24 | 07:00:15 | 31 Jul 2024 | | NICE recommends CYP2C19-ID Kit in final guidance |
| 15/07/24 | 07:00:06 | 15 Jul 2024 | | Breakthrough Device Designation from the U.S. FDA |
| 27/06/24 | 09:28:42 | 27 Jun 2024 | | Short extension to NICE publication date |
| 25/06/24 | 07:00:09 | 25 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 11:13:00 | 24 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 11:12:45 | 24 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 11:11:02 | 24 Jun 2024 | | Holding(s) in Company |
| 17/06/24 | 16:41:53 | 17 Jun 2024 | | Holding(s) in Company |
| 13/06/24 | 15:22:21 | 13 Jun 2024 | | Holding(s) in Company |
| 11/06/24 | 12:54:48 | 11 Jun 2024 | | Holding(s) in Company |
| 07/06/24 | 11:00:14 | 7 Jun 2024 | | Holding(s) in Company |
| 05/06/24 | 15:45:37 | 5 Jun 2024 | | Holding(s) in Company |
| 05/06/24 | 11:39:08 | 5 Jun 2024 | | Holding(s) in Company |
